top of page

News and Insights

May 29, 2025

Vittoria Biotherapeutics to Present VIPER-101 Phase 1 Trial at 2025 ASCO Annual Meeting (MyChesCo)

May 14, 2025

Nuvig Therapeutics Announces First Patient Dosed in Phase 2 CIDP Trial of NVG-2089 and Presentation of Phase 1 Data (Nuvig Therapeutics)

Apr 23, 2025

Treating Autoimmune Diseases: Four New Technologies To Watch (Forbes)

Apr 7, 2025

Who should we be watching on the USA biotech stage? (DDW-Online)

Apr 7, 2025

Epsilogen Announces Acquisition of TigaTx, Inc. to Create World’s Leading Pan-Isotype Cancer Antibody Company

Mar 21, 2025

The most funded women-led life sciences companies in the Bay Area in 2024

Dec 19, 2024

TigaTx Announces up to $35.5M in Funding from ARPA-H and NIH Awards to Advance First-in-Class Engineered IgA Monoclonal Antibody for Cancer and Infectious Diseases

Dec 5, 2024

Nuvig Therapeutics Announces $161 Million Series B Financing and Progression to Phase 2 Development with Novel, Second-Generation Immunomodulator

Nov 12, 2024

Vittoria Biotherapeutics Completes $25 Million in Private Financing to Propel Groundbreaking Cell Therapy Candidates

Oct 9, 2024

ShiraTronics Raises $66 Million in Oversubscribed Series B Financing to Advance Pioneering Treatment for Chronic Migraine

Sep 27, 2024

Odyssey Therapeutics Announces Formation of Scientific Advisory Board

Sep 26, 2023

Acesion clinches $47M in Series B raise to advance preclinical cardiac arrhythmia candidate through PhII

Sep 7, 2021

RMG-KB BIOACCESS FUND LAUNCHES with Worldwide Focus on Innovative Life Sciences Ventures

bottom of page